Format

Send to

Choose Destination
See comment in PubMed Commons below
Ann Oncol. 2006 Oct;17(10):1586-91. Epub 2006 Jul 20.

Long-term cardiac follow-up in survivors of a malignant bone tumour.

Author information

1
Subdivision Paediatric Oncology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands. c.a.j.brouwer@bkk.umcg.nl

Abstract

BACKGROUND:

Longitudinal studies of cardiac function in long-term childhood cancer survivors are scarce and frequently concern a median follow-up shorter than 13 years.

PATIENTS AND METHODS:

Cardiac assessment was performed in 22 doxorubicin-treated long-term survivors of a malignant bone tumour at median 22 years (range 15-27.5) post-treatment. Age at follow-up was 39 years (range 27-59) and cumulative dose of doxorubicin was 360 mg/m(2) (range 225-550). Cardiac function was assessed by echocardiography and (24-h) ECG. The results were compared with those of earlier assessments at 9 years (1992) and 14 years (1997) post-treatment.

RESULTS:

Systolic dysfunction was found in 27% (9% in 1997; P = 0.02) and diastolic dysfunction in 45% (18% in 1997; P = 0.02). Heart rate variability showed further deterioration compared with earlier results.

CONCLUSIONS:

Twenty-two years after doxorubicin-treatment, bone tumour survivors showed progressive cardiac dysfunction.

PMID:
16857723
DOI:
10.1093/annonc/mdl156
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Silverchair Information Systems
    Loading ...
    Support Center